TGFB1 and neoplasm: Chen et al. (2019) showed that the enhanced anti-tumor effect of anti-4-1BB immunotherapy stimulated by combination with an anti-CD73 blockade could be abrogated due to TGF-β in the TME, which sustained elevated CD73 expression on CD8+ T cells.